Ken Griffin Vera Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$34.09 - $46.71 $149,996 - $205,524	-4,400 Reduced 13.62%	27,900 $1.23 Million
Q2 2024 Aug 14, 2024	SELL	$33.72 - $48.82 $856,488 - $1.24 Million	-25,400 Reduced 44.02%	32,300 $1.17 Million
Q1 2024 May 15, 2024	BUY	$14.91 - $49.14 $830,487 - $2.74 Million	55,700 Added 2785.0%	57,700 $2.49 Million
Q4 2023 Feb 14, 2024	BUY	$9.29 - $16.0 $18,580 - $32,000	2,000 New	2,000 $30,000
Q2 2023 Aug 14, 2023	BUY	$6.11 - $17.83 $52,546 - $153,337	8,600 Added 477.78%	10,400 $166,000
Q1 2023 May 15, 2023	BUY	$5.41 - $18.3 $9,738 - $32,940	1,800 New	1,800 $13,000

184

55.1M

134K

156K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.15B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.